AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

635.252

-10.851-1.68%

Number of Gainers:3

Number of Losers:20

Number of Flat:20

PE:- -

High:645.436

Open:638.323

Low:632.715

Close:646.103

Volume:40.16M

Turnover:48.47M

Market Cap:90.31B

Float Cap:87.13B

Loading ...

Immuron Posts FY Revenue from Ordinary Activities of A$7.71 Million

Imricor, Philips Collaborate on Interventional Magnetic Resonance Lab Product for Cardiac Intervention

MT Newswires Live

Immuron - Revenue from Ordinary Activities up 5.9% to A$7.71 Mln for Year Ended June 30, 2026

THOMSON REUTERS

Immuron - Loss from Ordinary Activities A$3.8 Mln for Year Ended June 30, 2026

THOMSON REUTERS

Imricor Medical Systems, Inc - Imricor and Philips Launch Commercial Imr Lab Solution

THOMSON REUTERS

Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?

Simply Wall St.

3 ASX Stocks Estimated To Be Trading At Discounts Up To 47% Below Intrinsic Value

Simply Wall St.

Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn

Simply Wall St.

Bell Potter Upgrades PolyNovo to Buy from Hold; Price Target is AU$1.22

MT Newswires Live

Actinogen Medical Ltd - FY Loss from Ordinary Activities After Tax Attributable A$15.4 Mln

THOMSON REUTERS

Actinogen Medical Ltd - no Dividends Declared in Current or Prior Year

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd FY Basic EPS AUD 0.68

THOMSON REUTERS

Press Release: a Decade of Profitability Provides Foundation for CLINUVEL's U.S. Expansion

Cash Flow Stocks Retail Investors May Be Missing In Australia

Simply Wall St.

Biotron Ltd - Directors Recommend That no Dividend be Paid

THOMSON REUTERS

Biotron Ltd - FY Net Loss Attributable A$1.5 Mln

THOMSON REUTERS

Clinuvel Board Mulls Change to Group Structure, Potential Nasdaq Listing, ASX Delisting; Shares Dive 9%

MT Newswires Live

Clinuvel Pharmaceuticals Fiscal 2026 Earnings, Revenue Down

MT Newswires Live

Clinuvel Posts Fy2026 Net Profit After Tax of A$34 Million, Cash Reserves Rise to A$252 Million

Clinuvel Pharmaceuticals - to Relocate Operational Headquarters to United States

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/BK7508/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":635.2523,"timestamp":1789093013181,"preClose":646.1032,"halted":0,"volume":40155189,"delay":0,"changeRate":-0.016794,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-10.850891,"latestTime":"09-11 12:16:53 AEST","open":638.3234,"high":645.43604,"low":632.7152,"amount":48470277.18,"amplitude":0.019689,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789106400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789084800000,1789106400000]],"turnoverRate":0.001575,"increases":4,"decrements":20,"flats":19,"marketCap":90307554313.75,"floatMarketCap":87127383007.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":645.43604,"amplitude":0.019689,"preClose":646.1032,"low":632.7152,"latestPrice":635.2523,"volume":40155189,"delay":0,"open":638.3234,"prevYearClose":644.3692,"prevWeekClose":666.366,"prevMonthClose":656.138,"prevQuarterClose":464.145,"fiveDayClose":666.366,"twentyDayClose":541.582,"sixtyDayClose":464.274,"secType":"PLATE","market":"AU","turnoverRate":0.001575,"marketCap":90307554313.75,"floatMarketCap":87127383007.125,"timestamp":1789093013181,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":3,"down":20,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662031128","title":"Immuron Posts FY Revenue from Ordinary Activities of A$7.71 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662031128","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662031128?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:34","pubTimestamp":1787873652,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 MillionAug 28 -Immuron LtdIMC.AX:REVENUE FROM ORDINARY ACTIVITIES UP 5.9% TO A$7.71 MILLION FOR YEAR ENDED JUNE 30, 2026LOSS FROM ORDINARY ACTIVITIES A$3.8 MILLION FOR YEAR ENDED JUNE 30, 2026NO DIVIDENDS PAID OR DECLARED FOR YEAR ENDED JUNE 30, 2026Further company coverage:IMC.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662315210","title":"Imricor, Philips Collaborate on Interventional Magnetic Resonance Lab Product for Cardiac Intervention","url":"https://stock-news.laohu8.com/highlight/detail?id=2662315210","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662315210?lang=en_us&edition=fundamental","pubTime":"2026-08-28 07:18","pubTimestamp":1787872683,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems (ASX:IMR) collaborated with Royal Philips to offer an interventional magnetic resonance lab product for cardiac interventions, combining Philips' 1.5T magnetic resonance imagin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7503","IMR.AU","BK7007","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662039949","title":"Immuron - Revenue from Ordinary Activities up 5.9% to A$7.71 Mln for Year Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662039949?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:38","pubTimestamp":1787870323,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662039946","title":"Immuron - Loss from Ordinary Activities A$3.8 Mln for Year Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662039946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662039946?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:38","pubTimestamp":1787870323,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003626","title":"Imricor Medical Systems, Inc - Imricor and Philips Launch Commercial Imr Lab Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662003626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:17","pubTimestamp":1787869025,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","BK7503","IMR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032654","title":"Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032654","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662032654?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:21","pubTimestamp":1787865674,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is in focus after releasing its full year 2026 results, issuing earnings guidance for 2027, and declaring a US$1.62 per share dividend. This combination gives investors several fresh data points to assess.\nThe CSL share price has reacted sharply around these results, with a 30 day share price return of 45.48% and a 90 day share price return of 79.98% taking it to A$173.88, even though the 1 year total shareholder return is still down 16.24% and the 5 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-results-2027-guidance-and-its-dividen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-results-2027-guidance-and-its-dividen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7067","CSL.AU","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662396033","title":"3 ASX Stocks Estimated To Be Trading At Discounts Up To 47% Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2662396033","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662396033?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:04","pubTimestamp":1787857477,"startTime":"0","endTime":"0","summary":"As the Australian market navigates the implications of rising Consumer Price Index numbers and potential interest rate pressures, investors are keeping a close eye on undervalued opportunities amid these economic shifts. Identifying stocks that are trading below their intrinsic value can be a strategic move, especially in times when market conditions present both challenges and opportunities for discerning investors.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/3-asx-stocks-estimated-to-be-trading-at-discounts-up-to-47-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/3-asx-stocks-estimated-to-be-trading-at-discounts-up-to-47-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BGL.AU","NGI.AU","BK7162","BK7126","BK7141","SETM","NIC.AU","BK7016","BK7062","BK7015","ABV.AU","NXL.AU","SLC.AU","BK7084","BK7104","BK7051","ELS.AU","ING.AU","BK7095","BK7508","BK7505","DBB","BK7005","DUG.AU","PNV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662696084","title":"Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2662696084","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662696084?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:35","pubTimestamp":1787834131,"startTime":"0","endTime":"0","summary":"The market has Mesoblast trading around A$2.41 after a choppy week that left the stock down about 4% over seven days but still up double digits over one and three months. That price action suggests investors are torn between excitement over the story and concern about the cost of pursuing that growth.\nThe main takeaway from this earnings release is straightforward. Mesoblast reported its first full commercial year of RYONCIL revenue at US$115 million, yet still posted a net loss of US$57.5...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-shares-rally-meets-persistent-cash-burn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-shares-rally-meets-persistent-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7501","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662010706","title":"Bell Potter Upgrades PolyNovo to Buy from Hold; Price Target is AU$1.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2662010706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662010706?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:54","pubTimestamp":1787828045,"startTime":"0","endTime":"0","summary":"PolyNovo (ASX:PNV) has an average rating of overweight and mean price target of AU$1.28, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","BK7508","PNV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773768","title":"Actinogen Medical Ltd - FY Loss from Ordinary Activities After Tax Attributable A$15.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773768?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:29","pubTimestamp":1787812170,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662067773","title":"Actinogen Medical Ltd - no Dividends Declared in Current or Prior Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2662067773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662067773?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:29","pubTimestamp":1787812170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0EI:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778978","title":"Clinuvel Pharmaceuticals Ltd FY Basic EPS AUD 0.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778978?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:42","pubTimestamp":1787809325,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX9CGWMS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784347","title":"Press Release: a Decade of Profitability Provides Foundation for CLINUVEL's U.S. Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784347?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:42","pubTimestamp":1787809320,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and NEW YORK, Aug. 27, 2026  -- CLINUVEL PHARMACEUTICALS LTD  today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 . The Company has declared a dividend of $0.05 per ordinary share.\"CLINUVEL's cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,\" said Mr Peter Vaughan, CLINUVEL's Group Chief Financial Officer.\"This position provides us with flexibility to pursue an expansion strategy, continue investing through market cycles in key strategic areas, and allocate capital based on opportunity rather than necessity. As CLINUVEL builds its operations and presence in the capital markets in the United States, we can do so from a position of strength.\"Key Highlights, Year Ending 30 June 2026Consolidated Entity             30 June 2026  30 June 2025  Change YOY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067","BK4232","BK4022","EPP","BK4582","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771276","title":"Cash Flow Stocks Retail Investors May Be Missing In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771276?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:25","pubTimestamp":1787808304,"startTime":"0","endTime":"0","summary":"Central banks in Europe are still signalling possible rate hikes to contain inflation. That keeps pressure on broad equity valuations and makes reliable cash generation more valuable. When investors worry about the path of rates, stocks with strong cash flow support and discounts to estimated fair value can look appealing. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that fit that profile.\nThe stocks covered below are just a small sample, and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/cash-flow-stocks-retail-investors-may-be-missing-in-australi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/cash-flow-stocks-retail-investors-may-be-missing-in-australi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IIGF.AU","BK7016","VAP.AU","XJO.AU","GEAR.AU","BK4139","BK7067","QFN.AU","QRE.AU","DACE.AU","BK4211","BK4585","BK7508","E200.AU","IISV.AU","XKO.AU","BK4588","EIGA.AU","BEAR.AU","TLX.AU","GIVE.AU","BK7501","ZYAU.AU","SPHQ","MSB.AU","IMLC.AU","STW.AU","IOZ.AU","BK7503","BBOZ.AU","OZR.AU","VAS.AU","TLX","ISBC","SLF.AU","XAO.AU","OZF.AU","WTC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722629","title":"Biotron Ltd - Directors Recommend That no Dividend be Paid","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722629?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:22","pubTimestamp":1787800922,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44N12O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIT.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722625","title":"Biotron Ltd - FY Net Loss Attributable A$1.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722625?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:22","pubTimestamp":1787800922,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44N12O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BIT.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722365","title":"Clinuvel Board Mulls Change to Group Structure, Potential Nasdaq Listing, ASX Delisting; Shares Dive 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722365","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722365?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:09","pubTimestamp":1787800165,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said its board is considering a transaction under which the firm would change its group holding structure, seek a listing of its ordinary shares on the Nasdaq Stock Market, and delist from the ASX, according to a Thursday Australian bourse filing.It is establishing its new headquarters in the US, effective Jan. 1, 2027.Under a potential scheme of arrangement, a foreign holding company would become the new parent company of the Clinuvel, per the filing. Current shareholders of would receive ordinary shares in the holding company, representing an equivalent proportionate economic interest to their existing stake in Clinuvel. The holding company would then seek to list on the Nasdaq.The company's shares tumbled 9% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","LCLG","BK7508","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662240057","title":"Clinuvel Pharmaceuticals Fiscal 2026 Earnings, Revenue Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2662240057","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662240057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:00","pubTimestamp":1787799659,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  logged AU$0.668 in EPS for fiscal 2026, compared with AU$0.718 a year ago, a Thursday filing showed.For the 12 of months June 30, revenue was AU$94 million versus AU$95 million previously, the Australia-listed pharmaceutical company added.The board declared a final dividend of AU$0.05 per share, unchanged from a year earlier, payable Sept. 18 to shareholders on record as of Sept. 4.The biopharmaceutical company's shares rose nearly 2% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662272449","title":"Clinuvel Posts Fy2026 Net Profit After Tax of A$34 Million, Cash Reserves Rise to A$252 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662272449","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662272449?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:48","pubTimestamp":1787798911,"startTime":"0","endTime":"0","summary":"Clinuvel posts FY2026 net profit after tax of A$34 million, cash reserves rise to A$252 millionClinuvel posted FY2026 revenue of A$64 million, down 1%, with net profit after tax of A$34 million, down 6%.Total revenue including interest and other income reached A$101 million, down 4%.Cash reserves rose 12% to A$252 million, with net tangible assets backing per share at A$5.35, up 12%.Expenses totaled A$53 million, down 0.5%, with R&D at 34% of spending.Dividend held at A$0.05 per share, with basic earnings per share of A$0.68, down 6%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8sBmS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662772468","title":"Clinuvel Pharmaceuticals - to Relocate Operational Headquarters to United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2662772468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662772468?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:33","pubTimestamp":1787797998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUEBKRVRG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":126,"code":"91000000","status":"200"}]}}